- Details
- Charles Ryan, MD, and Veda Giri, MD discuss consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP inhibitors. Dr. Giri reflects on results from the Philadelphia Prostate Cancer Consensus Conference held in October 2019, which sought to address some of the challenges that have arisen as testing has increased and to develop a f...
|
- Details
- Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...
|
- Details
- Dan Petrylak joins Tom Keane to discuss PARP inhibition in castration-resistant prostate cancer. In this lecture, Dr. Petrylak discusses the germline DNA repair mutations involved in prostate cancer. This is a state of the art lecture establishing the rationale for the clinical trials evaluating PARP inhibitors in metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD...
|
- Details
- Oliver Sartor joins Alicia Morgans to highlight the recently published PROfound Trial. A phase III trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments. The PROfound trial was published in the New England Journal of Medicine...
|
- Details
- Alicia Morgans, Associate Professor of Medicine at Northwestern University, shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. Germline and somatic testing can have implications for patients in terms of their therapeutics and the main mutations. Morgans discusses the important germline and somatic mutations as well as the current data from clinical t...
|
- Details
- Wassim Abida, MD, describes his work to facilitate both better understanding of the genomic landscape of prostate cancer while simultaneously integrating new genomic information into clinical practice. In a conversation with Alicia Morgans, MD, MPH, Dr. Abida describes how to identify the subsets of patients that serve to benefit from targeted therapies, referencing the use of pembrolizumab for MS...
|
- Details
- Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...
|
- Details
- Neal Shore and Evan Yu share in a discussion on the evolving role of PARP inhibitors in the treatment of mCRPC. Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of PARP inhibitors in clinical development and what makes ea...
|
- Details
- (Length of Discussion: 8 min) Charles Ryan and Alan Bryce discuss TRITON2 results that provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with homologous recombination deficiency. Alan presents the molecular selection criteria, the design of the trial and the initial look at the first 85 patients in this study of he...
|
